These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28823518)

  • 1. Rivaroxaban in the Treatment of PICC-associated Upper Extremity Venous Thrombosis.
    Fan F; Zou Y; Zhang S; Zhang Y; Lan B; Song Q; Pei M; He L; Wu H; Du Y; Dart AM
    Clin Ther; 2017 Sep; 39(9):1882-1888. PubMed ID: 28823518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists.
    Eerenberg ES; Middeldorp S; Levi M; Lensing AW; Büller HR
    J Thromb Haemost; 2015 Sep; 13(9):1590-6. PubMed ID: 26179293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anticoagulants rivaroxaban and low molecular weight heparin prevent PICC-related upper extremity venous thrombosis in cancer patients.
    Lv S; Liu Y; Wei G; Shi X; Chen S; Zhang X
    Medicine (Baltimore); 2019 Nov; 98(47):e17894. PubMed ID: 31764785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
    Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
    Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2).
    Davies GA; Lazo-Langner A; Gandara E; Rodger M; Tagalakis V; Louzada M; Corpuz R; Kovacs MJ
    Thromb Res; 2018 Feb; 162():88-92. PubMed ID: 28416213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban or vitamin-K antagonists following early endovascular thrombus removal and stent placement for acute iliofemoral deep vein thrombosis.
    Sebastian T; Hakki LO; Spirk D; Baumann FA; Périard D; Banyai M; Spescha RS; Kucher N; Engelberger RP
    Thromb Res; 2018 Dec; 172():86-93. PubMed ID: 30391776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists.
    Di Nisio M; Ageno W; Rutjes AW; Pap AF; Büller HR
    Thromb Haemost; 2016 Jan; 115(2):424-32. PubMed ID: 26511068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study.
    Turpie AGG; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Ageno W
    Thromb Res; 2017 Jul; 155():23-27. PubMed ID: 28477534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis.
    Hanafy AS; Abd-Elsalam S; Dawoud MM
    Vascul Pharmacol; 2019 Feb; 113():86-91. PubMed ID: 29886103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of rivaroxaban for the treatment of PICC-related upper extremity deep vein thrombosis in cancer patients: a retrospective study.
    Xu J; Wang G; Chen X; Shen Y; Wang X; Wang H
    Thromb J; 2023 Feb; 21(1):15. PubMed ID: 36726149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban.
    Ferreira T; Huber SC; de Moraes Martinelli B; Junior AL; Menezes FH; Orsi FA; Bittar LF; de Oliveira LFG; Sodre LR; Mello TT; Rielli G; Colella MP; de Paula EV; Yamaguti-Hayakawa GG; Montalvão S; Annichino-Bizzacchi JM
    Vascul Pharmacol; 2020 Jan; 124():106608. PubMed ID: 31678199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
    Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High risk of deep vein thrombosis associated with peripherally inserted central catheters in lymphoma.
    Zhang X; Huang JJ; Xia Y; Li CF; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
    Oncotarget; 2016 Jun; 7(23):35404-11. PubMed ID: 27078849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The blind pushing technique for peripherally inserted central catheter placement through brachial vein puncture.
    Lee JM; Cho YK; Kim HM; Song MG; Song SY; Yeon JW; Yoon DY; Lee SY
    J Vasc Surg; 2018 Mar; 67(3):860-867. PubMed ID: 29153532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
    Vamos M; Cappato R; Marchlinski FE; Natale A; Hohnloser SH
    Europace; 2016 Dec; 18(12):1787-1794. PubMed ID: 26797248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
    Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
    Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recanalization of lower-limb deep veins as an index of efficacy of treatment for acute venous thrombosis].
    Kuznetsov MR; Sapelkin SV; Boldin BV; Leont'ev SG; Neskhodimov LA
    Angiol Sosud Khir; 2016; 22(3):82-8. PubMed ID: 27626254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.